398 reports of this reaction
3.6% of all KETAMINE HYDROCHLORIDE reports
#5 most reported adverse reaction
INFUSION SITE ERYTHEMA is the #5 most commonly reported adverse reaction for KETAMINE HYDROCHLORIDE, manufactured by Par Health USA, LLC. There are 398 FDA adverse event reports linking KETAMINE HYDROCHLORIDE to INFUSION SITE ERYTHEMA. This represents approximately 3.6% of all 11,206 adverse event reports for this drug.
Patients taking KETAMINE HYDROCHLORIDE who experience infusion site erythema should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
INFUSION SITE ERYTHEMA is moderately reported among KETAMINE HYDROCHLORIDE users, representing a notable but not dominant share of adverse events.
In addition to infusion site erythema, the following adverse reactions have been reported for KETAMINE HYDROCHLORIDE:
The following drugs have also been linked to infusion site erythema in FDA adverse event reports:
INFUSION SITE ERYTHEMA has been reported as an adverse event in 398 FDA reports for KETAMINE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
INFUSION SITE ERYTHEMA accounts for approximately 3.6% of all adverse event reports for KETAMINE HYDROCHLORIDE, making it a notable side effect.
If you experience infusion site erythema while taking KETAMINE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.